Showing results (161-170 of 183) with videos related to

Sort By:
Pageof 19
Biorxiv : the Preprint Server for Biology|April 10, 2023
Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersHusain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
Cancer Letters|September 25, 2024
RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growthSahar F Bannoura, Amro Aboukameel, Husain Yar Khan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I StudyErlene K Seymour, Husain Yar Khan, Yiwei Li, et al.
Molecular Cancer Therapeutics|September 13, 2023
Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung CancersHusain Yar Khan, Misako Nagasaka, Amro Aboukameel, et al.
Lung Cancer (Amsterdam, Netherlands)|September 5, 2021
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)Misako Nagasaka, Mohammad Fahad B Asad, Mohammed Najeeb Al Hallak, et al.
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Biorxiv : the Preprint Server for Biology|December 22, 2025
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerSahar F Bannoura, Husain Yar Khan, Amro Aboukameel, et al.
Molecular Cancer|March 14, 2025
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
JCO Oncology Advances|May 7, 2025
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT AlterationsIbrahim Azar, Husain Yar Khan, Sahar F Bannoura, et al.
Pageof 19